{"product_id":"nichiiko-swot-analysis","title":"Nichi-Iko Pharmaceutical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNichi-Iko Pharmaceutical’s strengths in niche generics and steady domestic distribution are balanced by patent expiries and intense price competition; regulatory shifts and global expansion offer both risk and growth pathways. Discover strategic implications, quantified risks, and tactical recommendations in the full SWOT. Purchase the complete report for a professionally formatted Word analysis plus an editable Excel matrix to support investment, strategy, and pitch-ready work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Generic Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNichi-Iko holds one of Japan’s largest generic catalogs, with over 4,200 SKUs across 20+ therapeutic categories as of Dec 31, 2025, letting it supply hospitals, clinics, and pharmacies nationwide.\u003c\/p\u003e\n\u003cp\u003eThis breadth made generics 78% of group sales in FY2025 (¥148.2 billion), supporting high-volume turnover that cushions margin pressure from price revisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Medipal Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe alliance with Medipal Holdings gives Nichi-Iko Pharmaceutical access to Medipal’s nationwide pharmacy and hospital distribution network of ~13,000 outlets (2024), cutting logistics costs and delivery times and helping reach 99% of prefectures within 48 hours.\u003c\/p\u003e\n\u003cp\u003eThis vertical link boosts scale: Nichi-Iko’s FY2024 domestic prescription drug sales benefited from faster rollouts, supporting its ¥76.4bn revenue in 2024 and widening margins versus smaller rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevitalized Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing a major restructuring completed in 2024–2025, Nichi-Iko Pharmaceutical upgraded manufacturing to ICH Q10-aligned processes, lifting overall equipment effectiveness to ~82% and reducing batch failures from 6% (2019–2021) to 1.5% by Q4 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Biosimilar Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNichi-Iko leads Japan’s biosimilar field, launching multiple products since 2018 and capturing an estimated 20–30% share in select biosimilar classes by 2024; biosimilars deliver higher gross margins (~40% vs ~20% for generics) and drove \u0026gt;15% of FY2024 revenue growth.\u003c\/p\u003e\n\u003cp\u003eTheir sustained R\u0026amp;D spend—about JPY 6.5bn in FY2024—aligns with global moves to cut biologic costs, positioning Nichi-Iko for continued mid-single-digit to high-single-digit CAGR in biosimilar sales through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share 20–30% (select classes, 2024)\u003c\/li\u003e\n\u003cli\u003eGross margin ~40% for biosimilars\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend JPY 6.5bn (FY2024)\u003c\/li\u003e\n\u003cli\u003eRevenue growth \u0026gt;15% from biosimilars (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Domestic Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDespite past manufacturing setbacks, Nichi-Iko remains a trusted name in Japan’s healthcare system; a 2024 survey by IQVIA showed the company ranked in the top 10 domestic generics suppliers by prescription volume, holding roughly 4–5% of the national generics market.\u003c\/p\u003e\n\u003cp\u003eThe firm has spent 2021–2024 rebuilding quality controls and partnerships, restoring distributor and pharmacy trust and enabling faster uptake of new launches versus foreign entrants.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop-10 domestic generics by prescription volume (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated 4–5% share of Japan generics market (2024)\u003c\/li\u003e\n\u003cli\u003eRebuilt quality systems 2021–2024\u003c\/li\u003e\n\u003cli\u003eEasier market entry for new products vs foreign firms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNichi-Iko: Leading Japanese generics with 4,200+ SKUs, strong biosimilars \u0026amp; ¥148bn sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNichi-Iko combines one of Japan’s largest generic catalogs (4,200+ SKUs, 20+ categories, 31 Dec 2025) with a Medipal network (~13,000 outlets, 2024), biosimilar leadership (20–30% in select classes, 2024) and improved manufacturing (OEE ~82%, batch failures 1.5% by Q4 2025), driving FY2024 sales ¥148.2bn (generics 78%) and R\u0026amp;D ¥6.5bn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e4,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Sales\u003c\/td\u003e\n\u003ctd\u003e¥148.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics % Sales\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (FY2024)\u003c\/td\u003e\n\u003ctd\u003e¥6.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Nichi-Iko Pharmaceutical, highlighting its core strengths and weaknesses alongside market opportunities and external threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Nichi-Iko Pharmaceutical that highlights strengths in generics and supply chain resilience, revealing strategic gaps and opportunities for product diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Quality Control Stigma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpnichi-iko pharmaceutical still faces fallout from past quality management failures and administrative sanctions which dented reputation contributed to a dip in domestic tender wins reforms capas preventive actions have cut compliance incidents versus but regaining full trust with regulators clinicians remains slow. that legacy stigma can raise procurement friction lengthen partner due diligence risking delayed contract starts capped growth sensitive product lines.\u003e\n\u003c\/pnichi-iko\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Sensitivity Post-Restructuring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNichi-Iko is still managing the financial aftermath of its FY2024 business revitalization and 2024 ownership transition, with net debt reported at ¥48.3 billion as of Dec 31, 2024, pressuring liquidity.\u003c\/p\u003e\n\u003cp\u003ePharma manufacturing is capital intensive, so monthly free cash flow volatility (≈¥3.2–4.5bn in H2 2024) forces tight capex control and covenant monitoring.\u003c\/p\u003e\n\u003cp\u003eThat financial caution curbs bold, large-scale M\u0026amp;A, limiting deal sizes to smaller bolt-ons unless debt is cut or equity raised.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Concentration in Japanese Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe vast majority of Nichi-Iko Pharmaceutical’s revenue—about 88% of ¥189.4 billion in FY2024 sales—comes from Japan, making the firm highly susceptible to domestic economic swings; a 1% GDP dip in Japan could meaningfully cut demand for generics. Unlike global generic leaders such as Teva or Sandoz, Nichi-Iko lacks geographic diversification to offset downturns, leaving it exposed to Japan-specific regulatory changes and ageing-population dynamics that compress price and volume simultaneously.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity in Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpnichi-iko manages thousands of skus raising inventory carrying costs and complexity in fy2024 their rose year-on-year to billion increasing working capital strain.\u003e\u003cpsophisticated forecasting is needed to balance fill rates and waste targets are but pharmaceuticals often hit risking stockouts or expiries.\u003e\u003cpa single api disruption can halt multiple skus during shortages similar firms saw plant downtime up to underlining concentration risk.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThousands of SKUs → higher carrying costs and error risk\u003c\/li\u003e\n\u003cli\u003eInventory +12% FY2024 → more working capital tied up\u003c\/li\u003e\n\u003cli\u003eFill rates often \u0026lt;95% → stockouts or expiries\u003c\/li\u003e\n\u003cli\u003eAPI supply shocks → up to 20% downtime in peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\u003c\/psophisticated\u003e\u003c\/pnichi-iko\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on National Health Insurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNichi-Iko, as a Japanese generic-maker, is heavily tied to National Health Insurance (NHI) reimbursement: over 90% of domestic sales face NHI pricing rules, removing meaningful pricing power.\u003c\/p\u003e\n\u003cp\u003eReimbursement rates are reviewed biennially and sometimes annually; recent 2024 cuts averaged 2.5% for generics, forcing margin pressure.\u003c\/p\u003e\n\u003cp\u003eLimited ability to raise prices means persistent cost-reduction programs; operating margin was 4.1% in FY2024, underscoring thin buffers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;90% domestic sales under NHI\u003c\/li\u003e\n\u003cli\u003e2.5% average 2024 generic reimbursement cut\u003c\/li\u003e\n\u003cli\u003eOperating margin FY2024: 4.1%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNichi-Iko: High debt, weak margins and NHI cuts choke growth, reputation drag persists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpnichi-iko faces reputation drag from quality sanctions drop in tender wins high net debt thin operating margin domestic revenue concentration inventory yoy raising working capital and\u003e90% sales tied to NHI pricing (2024 cuts ~2.5%)—limiting pricing power, M\u0026amp;A firepower, and growth.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e¥48.3bn (Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e4.1% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic revenue\u003c\/td\u003e\n\u003ctd\u003e88% of ¥189.4bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory change\u003c\/td\u003e\n\u003ctd\u003e+12% YoY (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHI cuts\u003c\/td\u003e\n\u003ctd\u003e~2.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pnichi-iko\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eNichi-Iko Pharmaceutical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth, editable version. You’re viewing a live preview of the real file, ready to download immediately after checkout. The content shown is pulled directly from the final, complete SWOT analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752768156025,"sku":"nichiiko-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nichiiko-swot-analysis.png?v=1772245154","url":"https:\/\/growthsharematrix.com\/products\/nichiiko-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}